Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Condition or disease
Central Serous Chorioretinopathy
Drug: rhuFab V2 [ranibizumab] ( Lucentis )
This is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 days (± 2 days) for 3 injections. Thereafter they are to be evaluated every month until month 12. Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
A history of persistent central serous chorioretinopathy present for at least 3 months Best-corrected visual acuity (BCVA) of 20/40 (73 letters on the ETDRS chart) to light perception as measured by ETDRS protocol refraction.
No signs of choroidal neovascularization
Documented subfoveal fluid by OCT
Active leak associated with the subfoveal fluid
The ability and willingness to provide written informed consent
Prior treatment with laser or PDT
Have uncontrolled hypertension
Have a history of thromboembolic events including stroke, transient ischemic attacks, and myocardial infarction
Have use of or need for continued anticoagulation therapy, except aspirin 325 mg/day.
Are receiving or require chronic concomitant therapy with systemic (> 5 mg) or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for 14 or more consecutive days at any time within 6 months prior to screening
Previously vitrectomized eyes.
Had allergic reactions to fluorescein dye or lack of venous access.
Any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), age related macular degeneration (AMD), retinal detachment, severe cataracts, etc.
An anticipated need for ocular surgery during the duration of the trial.
Within 1 month prior to screening, have had intra ocular surgeries (including cataract surgery) in the study eye.
Intravitreal triamcinolone or bevacizumab in the previous 2 months
Uncontrolled glaucoma (IOP > 24 mmHg) on greater than 3 medications.
Within 1 month prior to screening had YAG laser capsulotomy in the study eye
Have received any other systemic experimental drug within 12 weeks prior to enrollment.
Rubeosis iridis or neovascular glaucoma
Any untreated rhegmatogenous retinal detachment.
A visual acuity of worse than 20/400 in the fellow eye.
Unwilling or unable to follow or comply with all study related procedures.